Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 14, 2026, 6:15 PM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 10,671 matching trials from the live ClinicalTrials.gov search.

Filters: Condition: Infant, Newborn, Diseases Clear all

Conditions: Basal-Like Breast Carcinoma, BRCA1 Mutation Carrier, BRCA2 Mutation Carrier, Breast Carcinoma, Estrogen Receptor Negative, HER2/Neu Negative, Hereditary Breast and Ovarian Cancer Syndrome, Ovarian Carcinoma, Pancreatic Carcinoma, Progesterone Receptor Negative, Prostate Carcinoma, Recurrent Breast Carcinoma, Recurrent Fallopian Tube Carcinoma, Recurrent Ovarian Carcinoma, Recurrent Primary Peritoneal Carcinoma, Solid Neoplasm, Triple-Negative Breast Carcinoma
Interventions: Laboratory Biomarker Analysis, Pharmacological Study, Veliparib; Other · Drug
Lead sponsor: National Cancer Institute (NCI); NIH
Eligibility: 19 Years and older
Enrollment: 98 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009 – 2017
U.S. locations: 7
States / cities: Duarte, California • Los Angeles, California • Sacramento, California + 4 more

Conditions: Childhood Cancer, Cerebral Palsy, Chronic Lung Disease, Congenital Heart Disease, Congenital Metabolic Disorder, Gastrostomy
Interventions: GoalKeeper, Standard Care; Other
Lead sponsor: Stanford University; Other
Eligibility: 18 Years and older
Enrollment: 67 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2021
U.S. locations: 1
States / cities: Palo Alto, California

Conditions: Gastroschisis
Interventions: Not listed
Lead sponsor: Baylor College of Medicine; Other
Eligibility: Up to 3 Days
Enrollment: 27 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2026
U.S. locations: 1
States / cities: Houston, Texas

Conditions: Hemophilia A
Interventions: NXT007, Human Coagulation Factor VIII; Combination Product · Drug
Lead sponsor: Hoffmann-La Roche; Industry
Eligibility: 12 Years and older
Enrollment: 138 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2031
U.S. locations: 2
States / cities: Aurora, Colorado • Iowa City, Iowa

Conditions: Blood and Blood Disorders, Anemia, Neonatal, Hematologic Disease, Infant, Newborn, Diseases
Interventions: Fetoscopic laser surgery; Procedure
Lead sponsor: Assistance Publique - Hôpitaux de Paris; Other
Eligibility: 18 Years and older · Female only
Enrollment: 179 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2019
U.S. locations: 8
States / cities: Aurora, Colorado • Baltimore, Maryland • Cincinnati, Ohio + 5 more

Conditions: Bronchopulmonary Dysplasia, Bronchopulmonary Dysplasia Associated Pulmonary Hypertension, Pulmonary Hypertension, Premature Birth, Chronic Lung Disease of Prematurity
Interventions: Enteral L-citrulline; Dietary Supplement
Lead sponsor: The University of Texas Medical Branch, Galveston; Other
Eligibility: Up to 30 Weeks
Enrollment: 42 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2021
U.S. locations: 1
States / cities: Galveston, Texas

Conditions: Deglutition Disorders
Interventions: VFSS, FEES; Other
Lead sponsor: Baylor Research Institute; Other
Eligibility: 37 Weeks and older
Enrollment: 25 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2014
U.S. locations: 1
States / cities: Dallas, Texas

Conditions: Duchenne Muscular Dystrophy
Interventions: delandistrogene moxeparvovec, placebo; Genetic
Lead sponsor: Sarepta Therapeutics, Inc.; Industry
Eligibility: 4 Years to 7 Years · Male only
Enrollment: 126 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2024
U.S. locations: 23
States / cities: Little Rock, Arkansas • La Jolla, California • Los Angeles, California + 20 more

Conditions: Alagille Syndrome, Cholestasis, Biliary Atresia
Interventions: magnesium gluconate, magnesium sulfate; Drug
Lead sponsor: National Center for Research Resources (NCRR); NIH
Eligibility: 3 Years to 18 Years
Enrollment: 25 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: Started 2000
U.S. locations: 1
States / cities: Cincinnati, Ohio

Conditions: Amyotrophic Lateral Sclerosis, Muscular Dystrophy, Radiculopathy, Myopathy, Polyneuropathy and Mononeuropathies, Trauma Injury, Orthopedic Disorder
Interventions: Not listed
Lead sponsor: Beth Israel Deaconess Medical Center; Other
Eligibility: 18 Years to 90 Years
Enrollment: 223 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2013 – 2020
U.S. locations: 1
States / cities: Boston, Massachusetts

Conditions: Urethral Obstruction
Interventions: Fetal Intervention for LUTO; Procedure
Lead sponsor: Baylor College of Medicine; Other
Eligibility: 11 Weeks to 2 Years
Enrollment: 50 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2027
U.S. locations: 1
States / cities: Houston, Texas

Conditions: Neuropsychiatric Disorder, Neurological Disorder, Neurodevelopmental Disorder, Sleep
Interventions: Not listed
Lead sponsor: National Institute of Mental Health (NIMH); NIH
Eligibility: 30 Days to 99 Years
Enrollment: 237 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: Started 2012
U.S. locations: 1
States / cities: Bethesda, Maryland

Conditions: Niemann-Pick Disease, Type C1
Interventions: Hydroxypropyl-beta-cyclodextrin; Drug
Lead sponsor: Cyclo Therapeutics, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 13 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2020
U.S. locations: 2
States / cities: Oakland, California • Morristown, New Jersey

Conditions: Acute Hepatic Porphyria
Interventions: Not listed
Lead sponsor: Alnylam Pharmaceuticals; Industry
Eligibility: 12 Years and older
Enrollment: 136 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2021
U.S. locations: 8
States / cities: San Francisco, California • Miami, Florida • Ann Arbor, Michigan + 5 more

Conditions: Mucopolysaccharidosis IIIB
Interventions: SBC-103; Drug
Lead sponsor: Alexion Pharmaceuticals, Inc.; Industry
Eligibility: 2 Years to 12 Years
Enrollment: 11 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2017
U.S. locations: 2
States / cities: Minneapolis, Minnesota • Pittsburgh, Pennsylvania

Conditions: Heart Failure, Dilated Cardiomyopathy (DCM)
Interventions: Not listed
Lead sponsor: University of Illinois Chicago; Other
Eligibility: 18 Years and older
Enrollment: 1,500 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2024 – 2038
U.S. locations: 1
States / cities: Chicago, Illinois

Conditions: Juvenile Neuronal Ceroid Lipofuscinosis
Interventions: Mycophenolate mofetil, Liquid Placebo; Drug
Lead sponsor: University of Rochester; Other
Eligibility: 6 Years to 25 Years
Enrollment: 19 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2015
U.S. locations: 1
States / cities: Rochester, New York

Conditions: Pulmonary Hypertension, Heart Failure, Single Ventricle
Interventions: Actigraph to check activity levels at home; Device
Lead sponsor: Children's Mercy Hospital Kansas City; Other
Eligibility: 8 Years to 18 Years
Enrollment: 56 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2016 – 2022
U.S. locations: 1
States / cities: Kansas City, Missouri

Conditions: Long QT Syndrome Type 3
Interventions: Eleclazine, Eleclazine placebo; Drug
Lead sponsor: Gilead Sciences; Industry
Eligibility: 18 Years to 70 Years
Enrollment: 41 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2017
U.S. locations: 3
States / cities: Rochester, Minnesota • New York, New York • Rochester, New York

Conditions: Phenylketonuria (PKU)
Interventions: JNT-517; Drug
Lead sponsor: Otsuka Pharmaceutical Development & Commercialization, Inc.; Industry
Eligibility: 4 Years and older
Enrollment: 240 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2028
U.S. locations: 8
States / cities: Gainesville, Florida • Tampa, Florida • Portland, Oregon + 4 more

Conditions: Retinopathy of Prematurity
Interventions: Bevacizumab (Avastin); Drug
Lead sponsor: Children's Hospital Los Angeles; Other
Eligibility: 30 Weeks and older
U.S. locations: 1
States / cities: Los Angeles, California

Conditions: Venous Stenosis, Venous Occlusion
Interventions: Merit WRAPSODY® Cell Impermeable Endoprosthesis (WRAPSODY CIE); Device
Lead sponsor: Merit Medical Systems, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 250 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2030
U.S. locations: 14
States / cities: Dothan, Alabama • Phoenix, Arizona • Riverside, California + 11 more

Conditions: Gout, Hyperuricemia
Interventions: Uricase-PEG 20; Biological
Lead sponsor: EnzymeRx; Industry
Eligibility: 40 Years to 75 Years
Enrollment: 28 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2009 – 2010
U.S. locations: 2
States / cities: Miami, Florida • Duncansville, Pennsylvania

Conditions: Becker Muscular Dystrophy
Interventions: Tadalafil, Placebo; Drug
Lead sponsor: Cedars-Sinai Medical Center; Other
Eligibility: 18 Years to 55 Years · Male only
Enrollment: 48 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2010 – 2012
U.S. locations: 2
States / cities: Los Angeles, California

Search by objective public record fields.

Veliparib in Treating Patients With Malignant Solid Tumors That Do Not Respond to Previous Therapy

GoalKeeper: Intelligent Information Sharing for Children With Medical Complexity

Oral Care in Infants With Gastroschisis

A Clinical Study to Evaluate the Effects of NXT007 Compared to Factor VIII Prophylaxis in Participants With Hemophilia A

Randomized Controlled Trial Comparing a Conservative Management and Laser Surgery

Enteral L Citrulline Supplementation in Preterm Infants - Safety, Efficacy and Dosing

Comparing FEES to VFSS in Diagnosing Laryngeal Penetration and Aspiration in Infants in the NICU

A Gene Transfer Therapy Study to Evaluate the Safety and Efficacy of Delandistrogene Moxeparvovec (SRP-9001) in Participants With Duchenne Muscular Dystrophy (DMD)

Study of Magnesium Sulfate in Children With Reduced Bone Density Secondary to Chronic Cholestatic Liver Disease

Innovative Ultrasound Technology in Neuromuscular Disease

Standardized Prenatal Clinical Care for LUTO

Studying Childhood-onset Behavioral, Psychiatric, and Developmental Disorders

Study of the Pharmacokinetics of Trappsol and Effects on Potential Biomarkers of Niemann-Pick C1 (NPC1)

EXPLORE: A Natural History Study of Acute Hepatic Porphyria (AHP)

Safety, Pharmacokinetics, and Pharmacodynamics/Efficacy of SBC-103 in Mucopolysaccharidosis III, Type B (MPS IIIB)

UIC Multi-Ethnic DCM Registry

Cellcept for Treatment of Juvenile Neuronal Ceroid Lipofuscinosis

Frailty in Children With Cardiac Disease

Effect of Eleclazine on Shortening of the QT Interval, Safety, and Tolerability in Adults With Long QT Syndrome Type 3

A Long-Term Study of JNT-517 in Participants With Phenylketonuria

Use of Pan-vascular Endothelial Growth Factor Receptor (Pan-VEGF) Blockade for the Treatment of Retinopathy of Prematurity (ROP) (Compassionate Use BLOCK-ROP)

WRAP North America

Safety and Efficacy Study of Intramuscular Uricase-PEG 20

Tadalafil in Becker Muscular Dystrophy